Filing Details
- Accession Number:
- 0001651844-17-000004
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-06-21 16:49:52
- Reporting Period:
- 2017-06-19
- Filing Date:
- 2017-06-21
- Accepted Time:
- 2017-06-21 16:49:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1018735 | Nymox Pharmaceutical Corp | NYMX | In Vitro & In Vivo Diagnostic Substances (2835) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1651844 | George James Robinson | 10 East Lee Street Suite 2705 Baltimore MD 21202 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-06-19 | 600 | $3.77 | 3,008,150 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-19 | 500 | $3.78 | 3,008,650 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-19 | 2,000 | $3.79 | 3,010,650 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-19 | 1,900 | $3.80 | 3,012,550 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-20 | 2,000 | $3.75 | 3,014,550 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-20 | 300 | $3.76 | 3,014,850 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-20 | 2,200 | $3.77 | 3,017,050 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-20 | 500 | $3.79 | 3,017,550 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-21 | 500 | $3.75 | 3,018,050 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-21 | 3,500 | $3.76 | 3,021,550 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2017-06-21 | 1,000 | $3.77 | 3,022,550 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct | |
| No | 4 | P | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
| Common Stock | 49,550 | Indirect | Trust |
Billionaire Hedge Funds
